– USA, MA – NinePoint Medical, Inc., an emerging leader in the development of medical devices for advanced optical imaging, today announced the appointment of Christopher von Jako, Ph.D., as president and chief executive officer. Dr. von Jako brings to NinePoint Medical more than 20 years of experience in the global medical device industry and has demonstrated success leading and growing the value of organizations with early-stage commercial products.
“Chris is a passionate and technology-minded individual who deeply understands the dynamics of today’s medical device field,” said Tom Miller, chairman of NinePoint’s board of directors. “We believe his commercial insights and leadership experience will be incredibly valuable to NinePoint as we continue to expand the reach of our NvisionVLE™ Imaging System and plan for future growth.”
“NinePoint Medical has built strong momentum around their NvisionVLE Imaging System, which has been adopted by many of the leading hospitals in the U.S. and recently surpassed a milestone of 1,000 procedures completed since launch,” said Dr. von Jako. “I am very excited about the promise of this technology and the expertise of the management team, and look forward to working together to further advance NinePoint as a leader in optical imaging.”
Dr. von Jako joins NinePoint Medical from NeuroTherm, Inc., a medical device company focused on minimally invasive solutions for pain management, where he served as president and chief executive officer. NeuroTherm was divested to St. Jude Medical in August for $200 million. Prior to NeuroTherm, he was president of ActiViews, which developed and manufactured minimally invasive navigation solutions for image-guided procedures. Earlier in his career, Dr. von Jako served in senior executive roles of progressive responsibility with Integra LifeSciences, Covidien, Medtronic, and Radionics. He earned a double B.S. from Bates College, a M.S. from the Massachusetts Institute of Technology, and a Ph.D. from the University of Pécs Medical School.
About The NvisionVLE™ Imaging System
NinePoint Medical’s proprietary NvisionVLE Imaging System enables physicians to endoscopically view real-time, high-resolution, volumetric images of organs and tissues up to 3mm deep at seven micron resolution. Utilizing an advanced form of Fourier-domain optical coherence tomography (FD-OCT), NvisionVLE provides physicians and pathologists with cross-sectional, volumetric digital images of the esophagus – including below the surface of the tissue. This imaging information can be used to aid clinical decision-making relative to biopsy placement or treatment planning. The NvisionVLE™ Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization. The safety and effectiveness of this device for diagnostic analysis (i.e. differentiating normal versus specific abnormalities) in any tissue microstructure or specific disease has not been evaluated.
Developed at the Wellman Center for Photomedicine at Massachusetts General Hospital, this advanced OCT technology was licensed by NinePoint Medical in 2010 as part of the largest intellectual property agreement for medical device technology in the hospital’s history.
About NinePoint Medical, Inc.
NinePoint Medical is a transformational medical device company developing innovative, real-time imaging devices focused on dramatically improving patient care. The proprietary NvisionVLE™ Imaging System enables physicians, for the first time, to view real-time, high-resolution, volumetric images of esophageal tissue up to 3mm deep at seven micron resolution. Headquartered in Cambridge, Massachusetts, NinePoint Medical is backed by Third Rock Ventures, Prospect Venture Partners and Corning Incorporated (NYSE: GLW).
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.